X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (74353) 74353
Newsletter (7385) 7385
Book Review (5117) 5117
Publication (3324) 3324
Conference Proceeding (299) 299
Newspaper Article (284) 284
Book Chapter (227) 227
Dissertation (163) 163
Magazine Article (148) 148
Trade Publication Article (25) 25
Transcript (13) 13
Web Resource (12) 12
Reference (11) 11
Book / eBook (4) 4
Journal / eJournal (4) 4
Paper (4) 4
Data Set (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (59348) 59348
dexamethasone (42619) 42619
humans (37583) 37583
male (27354) 27354
animals (27129) 27129
female (24774) 24774
dexamethasone - pharmacology (23930) 23930
adult (13211) 13211
rats (13181) 13181
middle aged (11888) 11888
dexamethasone - therapeutic use (10121) 10121
dexamethasone - administration & dosage (9853) 9853
aged (7907) 7907
mice (7855) 7855
abridged index medicus (7781) 7781
research (7548) 7548
steroids (7168) 7168
cells, cultured (5817) 5817
oncology (5696) 5696
glucocorticoids - pharmacology (5613) 5613
endocrinology & metabolism (5231) 5231
glucocorticoids (5142) 5142
pharmacology & pharmacy (4932) 4932
treatment outcome (4812) 4812
corticosteroids (4563) 4563
biochemistry & molecular biology (4446) 4446
expression (4427) 4427
adolescent (4363) 4363
time factors (4329) 4329
hematology (4317) 4317
care and treatment (4084) 4084
analysis (4079) 4079
multiple myeloma (4034) 4034
hydrocortisone - blood (3990) 3990
dose-response relationship, drug (3874) 3874
central nervous system depressants (3571) 3571
cell line (3465) 3465
pregnancy (3409) 3409
child (3275) 3275
neurosciences (3252) 3252
cell biology (3245) 3245
therapy (3211) 3211
cancer (3177) 3177
drugs (3176) 3176
antineoplastic combined chemotherapy protocols - therapeutic use (3173) 3173
dexamethasone - adverse effects (2947) 2947
immunology (2884) 2884
reports (2868) 2868
chemotherapy (2850) 2850
inflammation (2812) 2812
surgery (2732) 2732
pediatrics (2724) 2724
rats, sprague-dawley (2703) 2703
kinetics (2673) 2673
cells (2666) 2666
apoptosis (2634) 2634
multiple myeloma - drug therapy (2632) 2632
drug therapy, combination (2520) 2520
receptors, glucocorticoid - metabolism (2519) 2519
glucocorticoids - administration & dosage (2500) 2500
bortezomib (2470) 2470
rna, messenger - metabolism (2434) 2434
ophthalmology (2429) 2429
drug therapy (2363) 2363
health aspects (2343) 2343
gene-expression (2319) 2319
gene expression (2317) 2317
glucocorticoids - therapeutic use (2298) 2298
rats, wistar (2224) 2224
aged, 80 and over (2184) 2184
medical research (2171) 2171
rats, inbred strains (2135) 2135
anti-inflammatory agents - therapeutic use (2112) 2112
psychiatry (2111) 2111
retrospective studies (2108) 2108
anti-inflammatory agents - pharmacology (2093) 2093
prospective studies (2081) 2081
medicine & public health (2036) 2036
dexamethasone - metabolism (2017) 2017
children (2002) 2002
medicine, general & internal (1978) 1978
disease models, animal (1961) 1961
child, preschool (1929) 1929
universities and colleges (1909) 1909
physiological aspects (1877) 1877
infant, newborn (1862) 1862
risk factors (1853) 1853
dosage and administration (1851) 1851
in-vitro (1846) 1846
medicine, experimental (1791) 1791
cortisol (1774) 1774
follow-up studies (1773) 1773
clinical neurology (1762) 1762
activation (1755) 1755
medicine, research & experimental (1741) 1741
gene expression regulation - drug effects (1736) 1736
physiology (1735) 1735
prevention (1673) 1673
proteins (1673) 1673
clinical trials (1665) 1665
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (75814) 75814
German (1382) 1382
French (1051) 1051
Japanese (969) 969
Chinese (805) 805
Spanish (647) 647
Russian (599) 599
Italian (304) 304
Portuguese (237) 237
Polish (204) 204
Korean (178) 178
Czech (83) 83
Dutch (68) 68
Turkish (45) 45
Persian (40) 40
Hungarian (37) 37
Danish (24) 24
Swedish (23) 23
Croatian (19) 19
Romanian (18) 18
Norwegian (17) 17
Bulgarian (16) 16
Serbian (16) 16
Ukrainian (15) 15
Finnish (12) 12
Slovak (11) 11
Hebrew (10) 10
Arabic (7) 7
Indonesian (5) 5
Slovenian (4) 4
Bosnian (2) 2
Icelandic (2) 2
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of clinical endocrinology and metabolism, ISSN 0021-972X, 02/2018, Volume 103, Issue 2, pp. 700 - 700
Journal Article
Clinical Ophthalmology, ISSN 1177-5483, 01/2016, Volume 10, p. 1586
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
Pulse therapy and its modifications in pemphigus: A six year study, 12/2003
Background: Dexamethasone-cyclophosphamide pulse (DCP) therapy for the pemphigus group of disorders is being widely used in India after its introduction in... 
Pemphigus, Dexamethasone-cyclophosphamide pulse, Dexamethasone-azathioprine pulse, Dexamethasone-methotrexate pulse
Journal
Environmental Toxicology and Pharmacology, ISSN 1382-6689, 01/2011, Volume 31, Issue 1, p. 258
Tricothecene mycotoxins, such as nivalenol, are toxic to leukocytes. To elucidate the molecular mechanism of nivalenol toxicity, we investigated the... 
Dexamethasone
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 12/2004, Volume 101, Issue 12, pp. 2788 - 2801
BACKGROUND. Modern intensive chemotherapy regimens have improved the prognosis for patients with adult acute lymphocytic leukemia (ALL). With these regimens,... 
acute lymphocytic leukemia (ALL) | hyperfractionated cyclophosphamide | vincristine | doxorubicin | long‐term follow‐up | and dexamethasone (Hyper‐CVAD) regimen | Acute lymphocytic leukemia (ALL) | Hyperfractionated cyclophosphamide | Long-term follow-up | And dexamethasone (Hyper-CVAD) regimen | Doxorubicin | Vincristine | MAINTENANCE CHEMOTHERAPY | COMPLETE REMISSION | STANDARD-RISK | BONE-MARROW-TRANSPLANTATION | ALLOGENEIC TRANSPLANT | CHILDHOOD | doxorubicin, and dexamethasone (Hyper-CVAD) regimen | THERAPY | ONCOLOGY | longterm follow-up | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHILDRENS CANCER GROUP | GROUP-B | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Risk | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Remission Induction | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Cyclophosphamide | Care and treatment | Dexamethasone | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 03/2015, Volume 201, pp. 32 - 40
Journal Article
Acta Ophthalmologica, ISSN 1755-375X, 08/2015, Volume 93, Issue 5, pp. 411 - 415
PurposeTo evaluate the safety and efficacy of 1.5% dexamethasone nanoparticle (DexNP) drops in eyes with non-infectious uveitic macular oedema and vitritis.... 
dexamethasone–cyclodextrin nanoparticle eye drops | non‐infectious uveitis | 1.5% dexamethasone nanoparticle eye drops | vitritis | intermediate uveitis | uveitic macular oedema | non-infectious uveitis | dexamethasone-cyclodextrin nanoparticle eye drops | MULTICENTER | CLINICAL-TRIAL | EFFICACY | DRUG-DELIVERY | DIFLUPREDNATE | 5% dexamethasone nanoparticle eye drops | TRIAMCINOLONE ACETONIDE | SUSPENSION | FLUOCINOLONE ACETONIDE IMPLANT | POSTERIOR UVEITIS | OPHTHALMOLOGY | COMPLICATIONS | Dexamethasone - chemistry | Glucocorticoids - administration & dosage | Prospective Studies | Follow-Up Studies | Nanoparticles - chemistry | Humans | Middle Aged | Dexamethasone - adverse effects | Male | Dexamethasone - analogs & derivatives | Visual Acuity - drug effects | Ophthalmic Solutions | Female | Glucocorticoids - adverse effects | Dexamethasone - administration & dosage | Uveitis - drug therapy | Pilot Projects | beta-Cyclodextrins - adverse effects | beta-Cyclodextrins - administration & dosage | beta-Cyclodextrins - chemistry | Eye Diseases - drug therapy | Macular Edema - drug therapy | Glucocorticoids - chemistry | Aged | Administration, Topical | Retina - pathology | Vitreous Body - drug effects | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Oftalmologi | Ophthalmology | termediate uveitis | Klinisk medicin
Journal Article
Acta Ophthalmologica, ISSN 1755-375X, 12/2018, Volume 96, Issue S261, pp. 106 - 106
Journal Article
Cancer, ISSN 0008-543X, 10/2015, Volume 121, Issue 20, pp. 3622 - 3630
The salvage infusional chemotherapy regimens, including DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin), VTD‐PACE (bortezomib, thalidomide,... 
multiple myeloma | CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) | VTD‐PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) | salvage | chemotherapy | DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) | VTD-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) | DEXAMETHASONE | MULTICENTER | BORTEZOMIB | TRANSPLANTATION | MAINTENANCE | THERAPY | ONCOLOGY | PHASE-1 | DCEP | LENALIDOMIDE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Dexamethasone - adverse effects | Male | Neoplasm Recurrence, Local - mortality | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Multiple Myeloma - drug therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Infusions, Parenteral | Etoposide - administration & dosage | Treatment Outcome | Thalidomide - administration & dosage | Bortezomib - administration & dosage | Bortezomib - adverse effects | Survival Analysis | Cisplatin - adverse effects | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Salvage Therapy - methods | Care and treatment | Chemotherapy | Usage | Cyclophosphamide | Multiple myeloma | Dosage and administration | Doxorubicin | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2018, Volume 182, Issue 2, pp. 231 - 244
Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma ( NDMM ) patients. This phase 1/2... 
newly diagnosed | multiple myeloma | oral | ixazomib | twice‐weekly | twice-weekly | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | PROTEASOME INHIBITOR IXAZOMIB | CYCLOPHOSPHAMIDE | AUTOLOGOUS TRANSPLANTATION | OPEN-LABEL | MAINTENANCE THERAPY | CARFILZOMIB | CONSOLIDATION THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Boron Compounds - administration & dosage | Dose-Response Relationship, Drug | Multiple Myeloma - drug therapy | Aged, 80 and over | Lenalidomide - pharmacokinetics | Adult | Female | Glycine - administration & dosage | Glycine - pharmacokinetics | Dexamethasone - administration & dosage | Drug Administration Schedule | Administration, Oral | Boron Compounds - pharmacokinetics | Treatment Outcome | Dexamethasone - pharmacokinetics | Disease-Free Survival | Lenalidomide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lenalidomide - adverse effects | Boron Compounds - adverse effects | Aged | Complications and side effects | Medical research | Care and treatment | Hyperglycemia | Dexamethasone | Multiple myeloma | Medicine, Experimental | Steroids | Toxicity | Pharmacology | Pharmacokinetics | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
Ultrasound in Obstetrics & Gynecology, ISSN 0960-7692, 09/2016, Volume 48, Issue S1, pp. 328 - 328
Journal Article
Journal Article